Celebrating 50 years of scientific
advancement – learn more

Visit JCR Japan

Visit JCR Japan

Home
Who we are
Innovation
Pipeline
Patients & families
Our commitment
Partnerships
Investors & media
Our products
Contact us

Copyright 2025, JCR Pharmaceuticals Co., Ltd. All Rights Reserved

JCR Pharmaceuticals announces licensing agreement with Menagen to commercialize Agalsidase Beta BS I.V. Infusion [JCR] across nine MENAT markets

October 1, 2025

|In News

|By Moises Zanetti

Back to Newsroom

Sitemap
Compliance
Privacy policy
Global policy
Cookie policy
Cookie settings

Copyright 2025, JCR Pharmaceuticals Co., Ltd. All Rights Reserved

Privacy Preference Center

Privacy Preferences